@article {Reynolds-Wright236, author = {John Joseph Reynolds-Wright and Richard A Anderson}, title = {Male contraception: where are we going and where have we been?}, volume = {45}, number = {4}, pages = {236--242}, year = {2019}, doi = {10.1136/bmjsrh-2019-200395}, publisher = {British Medical Journal Publishing Group}, abstract = {Progress in developing new reversible male contraception has been slow. While the hormonal approach has been clearly shown to be capable of providing effective and reversible contraception, there remains no product available. Currently, trials of a self-administered gel combination of testosterone and the progestogen Nestorone{\textregistered} are under way, complementing the largely injectable methods previously investigated. Novel long-acting steroids with both androgenic and progestogenic activity are also in early clinical trials. The non-hormonal approach offers potential advantages, with potential sites of action on spermatogenesis, and sperm maturation in the epididymis or at the vas, but remains in preclinical testing. Surveys indicate the willingness of men, and their partners, to use a new male method, but they continue to lack that opportunity.}, issn = {2515-1991}, URL = {https://srh.bmj.com/content/45/4/236}, eprint = {https://srh.bmj.com/content/45/4/236.full.pdf}, journal = {BMJ Sexual \& Reproductive Health} }